NO941780D0 - Method of treating TNF-dependent inflammation using tumor necrosis factor antagonists - Google Patents

Method of treating TNF-dependent inflammation using tumor necrosis factor antagonists

Info

Publication number
NO941780D0
NO941780D0 NO941780A NO941780A NO941780D0 NO 941780 D0 NO941780 D0 NO 941780D0 NO 941780 A NO941780 A NO 941780A NO 941780 A NO941780 A NO 941780A NO 941780 D0 NO941780 D0 NO 941780D0
Authority
NO
Norway
Prior art keywords
necrosis factor
tumor necrosis
factor antagonists
treating tnf
dependent inflammation
Prior art date
Application number
NO941780A
Other languages
Norwegian (no)
Other versions
NO941780L (en
Inventor
Craig A Smith
Cindy A Jacobs
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25484181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO941780(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of NO941780D0 publication Critical patent/NO941780D0/en
Publication of NO941780L publication Critical patent/NO941780L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO941780A 1992-09-15 1994-05-11 Method of treating TNF-dependent inflammation using tumor necrosis factor antagonists NO941780L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94623692A 1992-09-15 1992-09-15
PCT/US1993/008666 WO1994006476A1 (en) 1992-09-15 1993-09-14 Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists

Publications (2)

Publication Number Publication Date
NO941780D0 true NO941780D0 (en) 1994-05-11
NO941780L NO941780L (en) 1994-07-15

Family

ID=25484181

Family Applications (1)

Application Number Title Priority Date Filing Date
NO941780A NO941780L (en) 1992-09-15 1994-05-11 Method of treating TNF-dependent inflammation using tumor necrosis factor antagonists

Country Status (8)

Country Link
EP (1) EP0620739A4 (en)
JP (1) JPH07504203A (en)
KR (1) KR100232688B1 (en)
AU (1) AU670125B2 (en)
CA (1) CA2123593C (en)
NO (1) NO941780L (en)
NZ (1) NZ256293A (en)
WO (1) WO1994006476A1 (en)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0393438B1 (en) * 1989-04-21 2005-02-16 Amgen Inc. TNF-receptor, TNF-binding protein and DNA coding therefor
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
EP0670730B1 (en) * 1992-03-30 2003-06-04 Immunex Corporation Fusion protein comprising two tumor necrosis factor receptors
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
EP0772449A1 (en) * 1994-07-22 1997-05-14 F. Hoffmann-La Roche Ag Pharmaceutical compositions comprising a chimaeric tnf binding protein
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
EP0807181A1 (en) * 1995-02-03 1997-11-19 G.D. Searle & Co. NOVEL c-MPL LIGANDS
IL112834A (en) * 1995-03-01 2000-12-06 Yeda Res & Dev Pharmaceutical compositions for controlled release of soluble receptors
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US6656466B1 (en) 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
US5721121A (en) * 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US7012060B1 (en) 1995-07-14 2006-03-14 Applied Research Systems Ars Holding N.V. TNF receptor and steroid hormone in a combined therapy
AU715260B2 (en) 1995-07-14 2000-01-20 Laboratoires Serono Sa TNF receptor and steroid hormone in a combined therapy
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
MA24169A1 (en) * 1996-05-08 1997-12-31 Hoffmann La Roche TREATMENT OF ASTHMA USING TNFR-IG
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
SI0942740T1 (en) * 1996-12-06 2003-12-31 Amgen Inc. Combination therapy using a tnf binding protein for treating tnf-mediated diseases
AU5696198A (en) * 1996-12-06 1998-06-29 Amgen, Inc. Combination therapy using a tnf binding protein for treating tnf-mediated diseases
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
CA2290021A1 (en) * 1997-05-12 1998-11-19 The Kennedy Institute Of Rheumatology Suppression of tumor necrosis factor alpha and vascular endothelial growth factor in therapy
WO1999003999A1 (en) * 1997-07-17 1999-01-28 The Regents Of The University Of Michigan Methods and compositions for inhibiting the proinflammatory response
EP1097165A4 (en) * 1998-07-13 2001-09-12 Parkash S Gill Novel inhibitors of angiogenesis and tumor growth
US7067144B2 (en) 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
AU1345000A (en) * 1998-11-05 2000-05-22 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
TR200504220T2 (en) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Active lymphotoxin-beta receptor immunoglobulin chime A method for high level expression and purification of purified protein proteins and a method for purification of active lymphotoxin-beta receptor immunoglobulin chimeric proteins.
IL127851A0 (en) * 1998-12-30 1999-10-28 Applied Research Systems Inhibition of TNF activity
EP1022027A1 (en) * 1999-01-22 2000-07-26 Applied Research Systems ARS Holding N.V. Tumor necrosis factor antagonists and their use in endometriosis
CA2365824A1 (en) * 1999-04-02 2000-10-12 F. Ann Hayes Use of soluble tumor necrosis factor receptor for treatment heart failure
DE60040147D1 (en) * 1999-05-28 2008-10-16 Targeted Genetics Corp METHODS AND COMPOSITIONS FOR REDUCING TUMOR NEKROSIS FACTOR MIRROR (TNF) IN TNF ASSOCIATED DISEASES
EP1939300A1 (en) * 1999-05-28 2008-07-02 Targeted Genetics Corporation Methods and compositions for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
US6627199B1 (en) 1999-07-09 2003-09-30 Amgen Inc Isolation, identification and characterization of tmst2, a novel member of the TNF-receptor supergene family
CN101850120A (en) * 1999-07-21 2010-10-06 奥默罗斯公司 Be used for inhibition of pain, the solution of inflammation and cartilage degradation and method
WO2001011050A1 (en) 1999-08-04 2001-02-15 Amgen Inc. Fhm, A NOVEL MEMBER OF THE TNF LIGAND SUPERGENE FAMILY
WO2001010908A1 (en) 1999-08-04 2001-02-15 Amgen Inc. Ntr3, a member of the tnf-receptor supergene family
GB9927681D0 (en) * 1999-11-23 2000-01-19 Glaxo Group Ltd Protein
KR20020097241A (en) 2000-05-04 2002-12-31 에이브이아이 바이오파마 인코포레이티드 Splice-region antisense composition and method
CA2868614A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
KR100453877B1 (en) 2001-07-26 2004-10-20 메덱스젠 주식회사 METHOD OF MANUFACTURING Ig-FUSION PROTEINS BY CONCATAMERIZATION, TNFR/Fc FUSION PROTEINS MANUFACTURED BY THE METHOD, DNA CODING THE PROTEINS, VECTORS INCLUDING THE DNA, AND CELLS TRANSFORMED BY THE VECTOR
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
CN102755646A (en) 2002-07-19 2012-10-31 艾博特生物技术有限公司 Medicament for treating TNF alpha related disorder
CN1774445A (en) * 2002-08-16 2006-05-17 惠氏公司 Compositions and methods for treating RAGE-associated disorders
CA2498776A1 (en) * 2002-09-13 2004-03-25 The University Of Queensland Gene expression system based on codon translation efficiency
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
RS51041B (en) * 2003-02-28 2010-10-31 Ares Trading S.A. Liquid formulations of tumor necrosis factor-binding protein tbp-1
US20080241884A1 (en) * 2003-10-08 2008-10-02 Kenya Shitara Fused Protein Composition
TWI439284B (en) 2004-04-09 2014-06-01 Abbvie Biotechnology Ltd Multiple-variable dose regimen for treating tnfα-related disorders
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
CA2587617C (en) * 2004-11-12 2011-02-01 Xencor, Inc. Fc variants with altered binding to fcrn
AU2006230419A1 (en) * 2005-03-31 2006-10-05 Targeted Genetics Corporation Methods for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
EP1885397A4 (en) 2005-05-16 2010-01-20 Abbott Biotech Ltd Use of tnf inhibitor for treatment of erosive polyarthritis
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
CA2626804A1 (en) 2005-11-01 2007-08-09 Abbott Biotechnology Ltd. Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
US7785834B2 (en) 2005-11-10 2010-08-31 Ercole Biotech, Inc. Soluble TNF receptors and their use in treatment of disease
WO2008051306A1 (en) * 2006-10-20 2008-05-02 Ercole Biotech, Inc. Soluble tnf receptors and their use in treatment of disease
US7972599B2 (en) 2006-03-20 2011-07-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education Immunomodulation of inflammatory conditions utilizing Follistatin-like protein-1 and agents that bind thereto
US8007790B2 (en) 2006-04-03 2011-08-30 Stowers Institute For Medical Research Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
NZ571479A (en) 2006-04-05 2012-10-26 Abbott Biotech Ltd Antibody purification
WO2008063213A2 (en) 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
EP2703010A3 (en) 2006-04-10 2014-08-06 AbbVie Biotechnology Ltd Uses and compositions for treatment of rheumatoid arthritis
CA2564435A1 (en) 2006-04-10 2007-10-10 Abbott Biotechnology Ltd. Methods for monitoring and treating intestinal disorders
CN103316403B (en) 2006-06-30 2017-05-24 艾伯维生物技术有限公司 Automatic injection device
JP2010501622A (en) * 2006-08-28 2010-01-21 アレス トレーディング ソシエテ アノニム Purification method of Fc-fusion protein
CN101541825B (en) * 2006-08-28 2013-08-14 阿雷斯贸易股份有限公司 Process for the purification of Fc-fusion proteins
PL2061803T5 (en) 2006-08-28 2023-03-27 Ares Trading S.A. Process for the purification of fc-containing proteins
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
EP2073833A2 (en) 2006-10-20 2009-07-01 Biogen Idec MA Inc. Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
US8092998B2 (en) 2007-05-31 2012-01-10 Abbott Laboratories Biomarkers predictive of the responsiveness to TNFα inhibitors in autoimmune disorders
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
ES2564634T3 (en) 2007-06-14 2016-03-28 Galactica Pharmaceuticals, Inc. RAGE fusion proteins
EP2072527A1 (en) 2007-12-21 2009-06-24 Altonabiotec AG Fusion polypeptides comprising a SHBG dimerization component and uses thereof
US8658379B2 (en) 2008-01-29 2014-02-25 University of Pittsburgh—of the Commonwealth System of Higher Education Follistatin-like protein-1 as a biomarker for sepsis
CN102177240A (en) * 2008-08-12 2011-09-07 阿维斯塔根有限公司 An expression vector and a method thereof
CN102272326B (en) 2008-12-30 2014-11-12 森托科尔奥索生物科技公司 Serum markers predicting clinical response to anti-tnf antibodies in patients with ankylosing spondylitis
BRPI1012162A2 (en) 2009-04-29 2016-01-12 Abbott Biotech Ltd automatic injection device
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
BR112012013330A2 (en) 2009-12-02 2017-03-28 Acceleron Pharma Inc compositions and methods for increasing fc fusion protein serum half life
EP2513144A1 (en) 2009-12-16 2012-10-24 Philip Bosch Methods of treating interstitial cystitis
JO3417B1 (en) 2010-01-08 2019-10-20 Regeneron Pharma Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
HUE035618T2 (en) 2010-01-15 2018-05-28 Kirin Amgen Inc Antibody formulation and therapeutic regimens
CN102959088A (en) 2010-02-02 2013-03-06 艾博特生物技术有限公司 Methods and compositions for predicting responsiveness to treatment with TNF-a inhibitor
NZ702172A (en) 2010-04-21 2016-03-31 Abbvie Biotechnology Ltd Wearable automatic injection device for controlled delivery of therapeutic agents
WO2011146727A1 (en) 2010-05-19 2011-11-24 Philip Bosch Methods of treating interstitial cystitis
CN103079594B (en) 2010-06-03 2016-04-13 艾伯维生物技术有限公司 Be used for the treatment of purposes and the compositions of hidradenitis suppurativa (HS)
FR2962335B1 (en) 2010-07-12 2013-01-18 Cll Pharma USE OF PAT NONAPEPTIDE IN THE TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES
WO2012019099A2 (en) 2010-08-05 2012-02-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Follistatin-like-protein-1 as a biomarker for inflammatory disorders
EP2749305B1 (en) 2011-01-24 2017-11-01 AbbVie Biotechnology Ltd Automatic injection devices having overmolded gripping surfaces
BR112013023967A2 (en) 2011-03-18 2016-01-19 Abbvie Inc systems, devices and methods for assembling automatic injection devices and subsets thereof
MX2013011263A (en) 2011-03-29 2014-03-27 Abbvie Inc Improved shroud deployment in automatic injection devices.
EP4299093A3 (en) 2011-04-21 2024-03-13 AbbVie Inc. Wearable automatic injection device for controlled administration of therapeutic agents
UY34105A (en) 2011-06-03 2012-07-31 Lg Life Sciences Ltd STABLE LIQUID FORMULATION OF ETANERCEPT
WO2012170938A1 (en) 2011-06-08 2012-12-13 Acceleron Pharma Inc. Compositions and methods for increasing serum half-life
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
TWI589299B (en) 2011-10-11 2017-07-01 再生元醫藥公司 Compositions for the treatment of rheumatoid arthritis and methods of using same
WO2013059410A1 (en) 2011-10-18 2013-04-25 Coherus Biosciences, Inc. Etanercept formulations stabilized with xylitol
KR101525919B1 (en) * 2012-05-11 2015-06-03 가톨릭대학교 산학협력단 Bispecific antibody based on TNFR2 for preventing and traeating autoimmune disease
EA031324B1 (en) 2012-09-11 2018-12-28 Кохерус Байосайенсис, Инк. Correctly folded etanercept in high purity and excellent yield
CA2944605C (en) 2014-03-31 2023-10-17 Kirin-Amgen, Inc. Methods of treating nail and scalp psoriasis
US20170183376A1 (en) 2014-06-24 2017-06-29 Insight Biopharmaceuticals Ltd. Methods of purifying antibodies
ES2833506T3 (en) 2014-12-22 2021-06-15 Ares Trading Sa Liquid pharmaceutical composition
EP3078675A1 (en) 2015-04-10 2016-10-12 Ares Trading S.A. Induction dosing regimen for the treatment of tnf alpha mediated disorders
US20170306050A1 (en) 2016-04-08 2017-10-26 Gilead Sciences, Inc. Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
EP3257866A1 (en) 2016-06-17 2017-12-20 Academisch Medisch Centrum Modified anti-tnf antibody and use thereof in the treatment of ibd
US20190343425A1 (en) 2016-12-14 2019-11-14 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
JOP20190162A1 (en) 2016-12-30 2019-06-27 Biocad Joint Stock Co Aqueous Pharmaceutical Composition of a Recombinant Monoclonal Antibody to TNF?
EP3810095A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
KR20210030947A (en) 2018-07-03 2021-03-18 노파르티스 아게 Methods of treatment or selection of therapeutic agents for TNF inhibitor-resistant subjects using NLRP3 antagonists
BR112021003206A2 (en) 2018-08-29 2021-05-25 Regeneron Pharmaceuticals, Inc. methods and compositions for treating individuals with rheumatoid arthritis
KR20210122810A (en) 2019-01-31 2021-10-12 사노피 바이오테크놀로지 Anti-IL-6 receptor antibody for the treatment of juvenile idiopathic arthritis
CN110964119A (en) * 2019-12-05 2020-04-07 沣潮医药科技（上海）有限公司 Anti-malarial dimeric immunoadhesin, pharmaceutical composition and use
JP2023554200A (en) 2020-12-09 2023-12-26 エイチケー イノ．エヌ コーポレーション Anti-OX40L antibody, anti-OX40L and anti-TNFα bispecific antibody, and their uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
CA2485553A1 (en) * 1989-09-05 1991-03-21 Immunex Corporation Tumor necrosis factor - .alpha. and - .beta. receptors
WO1992013095A1 (en) * 1991-01-18 1992-08-06 Synergen, Inc. Methods for treating tumor necrosis factor mediated diseases
WO1994006431A1 (en) * 1992-09-22 1994-03-31 Cell Therapeutics, Inc. Novel epoxide-containing compounds

Also Published As

Publication number Publication date
AU4920993A (en) 1994-04-12
JPH07504203A (en) 1995-05-11
KR100232688B1 (en) 1999-12-01
EP0620739A4 (en) 1997-01-15
NO941780L (en) 1994-07-15
NZ256293A (en) 1997-06-24
CA2123593A1 (en) 1994-03-31
EP0620739A1 (en) 1994-10-26
AU670125B2 (en) 1996-07-04
CA2123593C (en) 2000-03-14
WO1994006476A1 (en) 1994-03-31

Similar Documents

Publication Publication Date Title
NO941780D0 (en) Method of treating TNF-dependent inflammation using tumor necrosis factor antagonists
AU3924993A (en) Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor
FI970918A0 (en) Compounds and methods for the treatment of cancer
FI945441A (en) New process for the preparation of 7beta-substituted-4-aza-5alpha-androstan-3-ones
NO932388L (en) Procedures for fracture-acid treatment of underwater formations
FI954119A (en) Procedure for the treatment of solid waste
NO307967B1 (en) Process and intermediates for the preparation of benzopyran compounds
DK329887D0 (en) METHOD OF TREATING ASBEST
GB2269393B (en) Method of treating MCrAlZ layers
KR930702896A (en) Tumor necrosis factor inhibitor
NO924815D0 (en) PROCEDURE FOR SURFACE TREATMENT OF AN OBJECTS
AU3973793A (en) Method of treating cancer
FI980091A0 (en) Procedure for the treatment of excess sludge
FI940869A0 (en) Process for the preparation of carboxylic anhydrides
BR9205496A (en) METHOD OF TREATING DIARRHEA
FI944984A (en) Compounds and Method for Controlling the In Vivo Production of IL-6
HUT60750A (en) Process for producing and applying inhibitors of tumour necrosis factor formation
ZA935831B (en) Methods of treating psoriasis employing substituted azaspiranes
ZA932731B (en) Method of treating gar-transformylase-dependent tumors
GB9201391D0 (en) Method of treatment
PL53839Y1 (en) Apparatus for orienting the grain pattern of concrete
ZA922012B (en) New method of treatment for prostatic cancer
BG95955A (en) Method for the preparation of therapeutical means of arthrosis treatment
NO950752L (en) Process water treatment process
DK18292D0 (en) METHOD OF COUNTERACTING ADVERSE EFFECTS OF BENZODIAZEPINES

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application